Sugi Predict

Sugi Predict / Compounds / SCHEMBL20549706

SCHEMBL20549706

SCHEMBL20549706

CC(C)n1cnc2c(Nc3cccc(N)c3)nc(Cl)nc21

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK5 Q00535 9/20 0.73
▸ CDK5R1 Q15078 9/20 0.73
▸ CCNA2 P20248 8/20 0.73
▸ CDK2 P24941 8/20 0.73
▸ CCNA1 P78396 8/20 0.73
▸ DYRK1A Q13627 7/20 0.70
▸ NPC1 O15118 1/20 0.61
▸ POLB P06746 1/20 0.61
▸ CDK1 P06493 7/20 0.58
▸ CCNB1 P14635 3/20 0.58
▸ CCNB2 O95067 1/20 0.58
▸ CCNB3 Q8WWL7 1/20 0.58
▸ EIF2AK2 P19525 1/20 0.57
▸ GSK3B P49841 1/20 0.57
▸ MERTK Q12866 1/20 0.57
▸ CLK1 P49759 4/20 0.56
▸ CLK2 P49760 4/20 0.56
▸ CLK4 Q9HAZ1 4/20 0.56
▸ CDK4 P11802 1/20 0.56
▸ CCND3 P30281 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5840458 0.89 CDK5 (0.74) CDK5CDK5R1CCNA2CDK2CCNA1
SCHEMBL29444630 0.89 CDK5 (0.74) CDK5CDK5R1CCNA2CDK2CCNA1
SCHEMBL5839477 0.87 CDK5 (0.72) CDK5CDK5R1CCNA2CDK2CCNA1
SCHEMBL22388789 0.87 CDK1 (0.59) CDK5CDK5R1CCNA2CDK2CCNA1
SCHEMBL5827777 0.87 CDK5 (0.79) CDK5CDK5R1CCNA2CDK2CCNA1
SCHEMBL20549679 0.86 CDK1 (0.58) CDK5CDK5R1CCNA2CDK2CCNA1
SCHEMBL5839709 0.85 CDK5 (0.69) CDK5CDK5R1CCNA2CDK2CCNA1
SCHEMBL20028762 0.85 CLK1 (0.67) CDK5CDK5R1CCNA2CDK2CCNA1
SCHEMBL17212873 0.84 CDK5 (1.00) CDK5CDK5R1CCNA2CDK2CCNA1
SCHEMBL31072387 0.83 CDK1 (0.78) CDK5CDK5R1CCNA2CDK2CCNA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE50776-E1 Inhibitors of cyclin-dependent kinases DANA-FARBER CANCER INSTITUTE, INC. (US) 2026-02-03 — — US disclosed
US-12098154-B2 Inhibitors of cyclin-dependent kinases DANA-FARBER CANCER INSTITUTE, INC. (US) 2024-09-24 — — US disclosed
US-20230183240-A9 INHIBITORS OF CYCLIN-DEPENDENT KINASES DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-06-15 — — US disclosed
US-20230183240-A9 INHIBITORS OF CYCLIN-DEPENDENT KINASES DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-06-15 — — US disclosed
US-20230183240-A9 INHIBITORS OF CYCLIN-DEPENDENT KINASES DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-06-15 — — US disclosed
EP-3273966-B1 INHIBITORS OF CYCLIN-DEPENDENT KINASES DANA FARBER CANCER INST INC (US) 2023-05-03 — — EP disclosed
EP-3273966-B1 INHIBITORS OF CYCLIN-DEPENDENT KINASES DANA FARBER CANCER INST INC (US) 2023-05-03 — — EP disclosed
US-20220242865-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-08-04 — — US disclosed
US-11325910-B2 Inhibitors of cyclin-dependent kinases DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-05-10 — — US disclosed
US-11325910-B2 Inhibitors of cyclin-dependent kinases DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-05-10 — — US disclosed
CN-107427521-B Inhibitors of cyclin dependent kinases 达纳-法伯癌症研究所股份有限公司 2021-08-03 — — CN disclosed
US-20200277292-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-09-03 — — US disclosed
US-20200277292-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-09-03 — — US disclosed
US-10550121-B2 Inhibitors of cyclin-dependent kinases DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-02-04 — — US disclosed
US-10550121-B2 Inhibitors of cyclin-dependent kinases DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-02-04 — — US disclosed
US-20190315747-A9 INHIBITORS OF CYCLIN-DEPENDENT KINASES DANA-FARBER CANCER INSTITUTE, INC. (US) 2019-10-17 — — US disclosed
US-20190315747-A9 INHIBITORS OF CYCLIN-DEPENDENT KINASES DANA-FARBER CANCER INSTITUTE, INC. (US) 2019-10-17 — — US disclosed
US-20180319801-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES DANA-FARBER CANCER INSTITUTE, INC. (US) 2018-11-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11325910-B2 Inhibitors of cyclin-dependent kinases CDK3, CDK13, CDK1 CDK5 18/4885CDK5R1 51/4885CCNA2 27/4885
US-20220242865-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES CDK3, CDK13, CDK1 CDK5 18/4885CDK5R1 51/4885CCNA2 27/4885
US-20200277292-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES CDK3, CDK13, CDK1 CDK5 18/4885CDK5R1 51/4885CCNA2 27/4885
US-10550121-B2 Inhibitors of cyclin-dependent kinases CDK3, CDK13, CDK1 CDK5 18/4885CDK5R1 51/4885CCNA2 27/4885
US-20180319801-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES CDK3, CDK13, CDK1 CDK5 18/4885CDK5R1 51/4885CCNA2 27/4885
US-12098154-B2 Inhibitors of cyclin-dependent kinases CDK3, CDK13, CDK1 CDK5 18/4885CDK5R1 51/4885CCNA2 27/4885
US-20190315747-A9 INHIBITORS OF CYCLIN-DEPENDENT KINASES CDK3, CDK13, CDK1 CDK5 18/4885CDK5R1 51/4885CCNA2 27/4885
US-20230183240-A9 INHIBITORS OF CYCLIN-DEPENDENT KINASES CDK3, CDK13, CDK1 CDK5 18/4885CDK5R1 51/4885CCNA2 27/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.